Delving into the Latest Updates on Azanta Danmark A/S with Synapse

Overview

As many as 85 % of renal transplant patients may suffer from viral warts with a high degree of treatment resistance. Promising results of hLAC (human lactalbumin complex with lipid) point to a beneficial effect without noticeable side effects of bLAC (bovine lactalbumin complex with lipid). The aim of first clinical trial with bLAC is to show proof of concept in treatment of cutaneous wart lesions on hands and/or feet after local administration of bLAC in two dose groups to immune suppressed, kidney transplanted patients.

Start Date01 Mar 2008

Sponsor / Collaborator

Azanta Danmark A/S

100 Clinical Results associated with Azanta Danmark A/S

Login to view more data

0 Patents (Medical) associated with Azanta Danmark A/S

Login to view more data

100 Deals associated with Azanta Danmark A/S

Login to view more data

100 Translational Medicine associated with Azanta Danmark A/S

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

4

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Recombinant human mannose-binding lectin(NatImmune A/S) ( LMAN1 )	Infectious Diseases More	Discontinued
131I-COU-1	Colonic Cancer More	Pending
BAMLET(NatImmune A/S)	Bladder Cancer More	Pending
Bovine lactalbumin complex with lipid(NatImmune A/S)	Warts More	Pending